- Home
- BIDU vs GH Comparison
BIDU vs GH Comparison
Compare BIDU & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIDU | GH |
|---|---|---|
| Founded | 2000 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.6B | 22.9B |
| IPO Year | 2005 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BIDU | GH |
|---|---|---|
| Price | $79.04 | $183.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 30 | 26 |
| Target Price | $134.66 | ★ $202.24 |
| AVG Volume (30 Days) | ★ 1.8M | 1.7M |
| Earning Date | 11-16-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $982,021,000.00 |
| Revenue This Year | N/A | $38.43 |
| Revenue Next Year | $6.41 | $35.16 |
| P/E Ratio | $42.45 | ★ N/A |
| Revenue Growth | N/A | ★ 32.88 |
| 52 Week Low | $76.73 | $74.55 |
| 52 Week High | $165.30 | $191.05 |
Technical Indicators
Market Signals| Indicator | BIDU | GH |
|---|---|---|
| Relative Strength Index (RSI) | 35.24 | 64.39 |
| Support Level | N/A | $154.16 |
| Resistance Level | $93.83 | $187.28 |
| Average True Range (ATR) | 1.77 | 8.35 |
| MACD | 0.04 | 1.88 |
| Stochastic Oscillator | 25.03 | 97.47 |
Price Performance
Historical ComparisonAbout BIDU Baidu Inc. ADS
Most of Baidu's revenue comes from Baidu core, with the rest coming from video-streaming subsidiary iQiyi. The firm's main businesses include online marketing services from its search engine, AI cloud infrastructure, AI applications, AI marketing, and autonomous driving.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.